313 related articles for article (PubMed ID: 38276041)
1. Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.
Del Negro I; Pez S; Versace S; Marziali A; Gigli GL; Tereshko Y; Valente M
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38276041
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L
Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy.
Yadav SK; Ito K; Dhib-Jalbut S
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834203
[TBL] [Abstract][Full Text] [Related]
4. Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications.
Wang X; Liang Z; Wang S; Ma D; Zhu M; Feng J
Curr Neuropharmacol; 2022; 20(7):1413-1426. PubMed ID: 34191698
[TBL] [Abstract][Full Text] [Related]
5. The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?
Parodi B; Kerlero de Rosbo N
Front Immunol; 2021; 12():718220. PubMed ID: 34621267
[TBL] [Abstract][Full Text] [Related]
6. Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?
Martinelli V; Albanese M; Altieri M; Annovazzi P; Arabi S; Bucello S; Caleri F; Cerqua R; Costanzi C; Cottone S; Dalla Costa G; Direnzo V; Fantozzi R; Favaretto A; Lorefice L; Montini F; Noce A; Plewnia K; Repice AM; Sacco R; Vecchio D
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):935-946. PubMed ID: 35179760
[TBL] [Abstract][Full Text] [Related]
7. Multiple Sclerosis and Microbiome.
Preiningerova JL; Jiraskova Zakostelska Z; Srinivasan A; Ticha V; Kovarova I; Kleinova P; Tlaskalova-Hogenova H; Kubala Havrdova E
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327624
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis.
Xu L; Zhang C; He D; Jiang N; Bai Y; Xin Y
Life Sci; 2020 Jul; 253():117747. PubMed ID: 32376270
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
Tsai CC; Jette S; Tremlett H
J Neurol; 2024 Mar; 271(3):1108-1123. PubMed ID: 38078977
[TBL] [Abstract][Full Text] [Related]
10. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.
Bianchimano P; Britton GJ; Wallach DS; Smith EM; Cox LM; Liu S; Iwanowski K; Weiner HL; Faith JJ; Clemente JC; Tankou SK
Microbiome; 2022 Oct; 10(1):174. PubMed ID: 36253847
[TBL] [Abstract][Full Text] [Related]
11. Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics.
Ding M; Lang Y; Shu H; Shao J; Cui L
Front Immunol; 2021; 12():742449. PubMed ID: 34707612
[TBL] [Abstract][Full Text] [Related]
12. Hypothesis of a potential BrainBiota and its relation to CNS autoimmune inflammation.
Elkjaer ML; Simon L; Frisch T; Bente LM; Kacprowski T; Thomassen M; Reynolds R; Baumbach J; Röttger R; Illes Z
Front Immunol; 2022; 13():1043579. PubMed ID: 36532064
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome and multiple sclerosis: New insights and perspective.
Esmaeil Amini M; Shomali N; Bakhshi A; Rezaei S; Hemmatzadeh M; Hosseinzadeh R; Eslami S; Babaie F; Aslani S; Torkamandi S; Mohammadi H
Int Immunopharmacol; 2020 Nov; 88():107024. PubMed ID: 33182024
[TBL] [Abstract][Full Text] [Related]
14. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.
Camara-Lemarroy CR; Metz LM; Yong VW
World J Gastroenterol; 2018 Oct; 24(37):4217-4223. PubMed ID: 30310254
[TBL] [Abstract][Full Text] [Related]
15. The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis.
Freedman SN; Shahi SK; Mangalam AK
Neurotherapeutics; 2018 Jan; 15(1):109-125. PubMed ID: 29204955
[TBL] [Abstract][Full Text] [Related]
16. Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis.
Ullah H; Tovchiga O; Daglia M; Khan H
Curr Neuropharmacol; 2021; 19(11):1966-1983. PubMed ID: 33596808
[TBL] [Abstract][Full Text] [Related]
17. Impacts of microbiome metabolites on immune regulation and autoimmunity.
Haase S; Haghikia A; Wilck N; Müller DN; Linker RA
Immunology; 2018 Jun; 154(2):230-238. PubMed ID: 29637999
[TBL] [Abstract][Full Text] [Related]
18. The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
Vacaras V; Muresanu DF; Buzoianu AD; Nistor C; Vesa SC; Paraschiv AC; Botos-Vacaras D; Vacaras C; Vithoulkas G
J Neuroimmunol; 2023 May; 378():578087. PubMed ID: 37058852
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal Tract, Microbiota and Multiple Sclerosis (MS) and the Link Between Gut Microbiota and CNS.
Yousefi B; Babaeizad A; Banihashemian SZ; Feyzabadi ZK; Dadashpour M; Pahlevan D; Ghaffari H; Eslami M
Curr Microbiol; 2022 Dec; 80(1):38. PubMed ID: 36527519
[TBL] [Abstract][Full Text] [Related]
20. The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis.
Ladakis DC; Bhargava P
CNS Drugs; 2023 Feb; 37(2):117-132. PubMed ID: 36690786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
